Biograil Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $32.7M

  • Investors
  • 11

Biograil General Information

Description

Developer of an ingestible capsule technology designed for oral delivery of biologics. The company's technology utilizes a spring-loaded grabbing mechanism and biodegradable polymers to deliver macromolecules into the stomach's mucosal wall, providing pharmaceutical companies with a method to transform injectable therapeutics into oral medications that help with patient adherence and treatment outcomes.

Contact Information

Website
www.biograil.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Langebjerg 1
  • 4000 Roskilde
  • Denmark
+45 30
Primary Industry
Therapeutic Devices
Other Industries
Drug Delivery
Biotechnology
Other Devices and Supplies
Vertical(s)
Digital Health, Wearables & Quantified Self, HealthTech
Corporate Office
  • Langebjerg 1
  • 4000 Roskilde
  • Denmark
+45 30

Biograil Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biograil Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 04-Nov-2026 $32.7M Completed Clinical Trials - Phase 1
8. Later Stage VC 05-Apr-2024 Completed Pre-Clinical Trials
7. Grant 04-Mar-2022 Completed Pre-Clinical Trials
6. Seed Round 17-Feb-2022 Completed Pre-Clinical Trials
5. Seed Round 09-Jan-2021 Completed Pre-Clinical Trials
4. Accelerator/Incubator 09-Oct-2020 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 20-Jan-2020 Cancelled Pre-Clinical Trials
2. Seed Round 20-Jan-2020 $3.78M $3.78M Completed Pre-Clinical Trials
1. Angel (individual) Completed Pre-Clinical Trials
To view Biograil’s complete valuation and funding history, request access »

Biograil Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 33,344 $26.34 $26.34 1x $26.34 6.78%
Ordinary 20,340 $21.08 $21.08 1x $21.08 4.13%
To view Biograil’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Biograil Patents

  • 67

    Total Documents Applications and Grants

  • Total Patents Families

  • 24

    Granted

  • 33

    Pending

  • Expiring in next 12 mo

Biograil Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026132285-A1 Oral drug delivery device with helical spring Pending 19-Dec-2024
US-12521537-B2 Oral drug delivery device with cover release Active 29-Apr-2024
US-20250332395-A1 Oral drug delivery device with cover release Active 29-Apr-2024
US-20260166289-A1 Oral drug delivery device with cover release Pending 29-Apr-2024
WO-2025228948-A1 Oral drug delivery device with cover release Pending 29-Apr-2024 A61M31/002
To view Biograil’s complete patent history, request access »

Biograil Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biograil Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Acondis Venture Capital Minority
Kinled Holding Family Office Minority
Lilly USA Corporation Minority
Roquette Ventures Corporate Venture Capital Minority
Evonik Venture Capital Corporate Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Biograil FAQs

  • When was Biograil founded?

    Biograil was founded in 2019.

  • Where is Biograil headquartered?

    Biograil is headquartered in Roskilde, Denmark.

  • What is the size of Biograil?

    Biograil has 31 total employees.

  • What industry is Biograil in?

    Biograil’s primary industry is Therapeutic Devices.

  • Is Biograil a private or public company?

    Biograil is a Private company.

  • What is the current valuation of Biograil?

    The current valuation of Biograil is .

  • What is Biograil’s current revenue?

    The current revenue for Biograil is .

  • How much funding has Biograil raised over time?

    Biograil has raised $42.6M.

  • Who are Biograil’s investors?

    Acondis, Kinled Holding, Lilly USA, Roquette Ventures, and Evonik Venture Capital are 5 of 11 investors who have invested in Biograil.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process